WALTHAM, Mass., Sept. 12 /PRNewswire-FirstCall/ -- Inverness Medical
Innovations, Inc. (Amex: IMA), a leading manufacturer and marketer of rapid
diagnostic products for the consumer and professional markets, announced
today the successful completion of its acquisition of Cholestech
Corporation (Nasdaq: CTEC). Inverness completed the acquisition through the
merger of a wholly owned subsidiary with and into Cholestech, after
Cholestech's shareholders approved the deal at a shareholder's meeting
today. Cholestech is a leading provider of diagnostic tools and information
for immediate risk assessment and therapeutic monitoring of heart disease
and inflammatory disorders.

"The acquisition of Cholestech together with our recent and pending
acquisitions, provides Inverness with the unique ability to assess cardiac
risk, diagnose cardiac conditions and potentially monitor the condition and
response to therapy of cardiac patients. The Cholestech LDX System is one
of the most established and respected monitoring platforms available to
physicians and patients and we believe that this added access to
physicians' office laboratories will provide broad benefits for many
Inverness and Biosite products," stated Ron Zwanziger, Chairman, President
and Chief Executive Officer of Inverness. "We welcome Cholestech and its
associates to the Inverness Medical family."

As a result of the merger, Cholestech stockholders received .43642
shares of Inverness common stock for each Cholestech share, resulting in an
aggregate issuance of approximately 6,801,946 shares of Inverness common
stock. Additionally, each option to purchase shares of Cholestech common
stock outstanding prior to the completion of the acquisition has been
converted into a right to acquire Inverness shares, at the same exchange
ratio of .43642. Cholestech shares will cease trading at the close of
business on September 12, 2007 and will be delisted from the Nasdaq.

About Inverness:

By developing new capabilities in near-patient diagnosis, monitoring
and health management, Inverness Medical Innovations enables individuals to
take charge of improving their health and quality of life. A global leader
in rapid point-of-care diagnostics, Inverness' products, as well as its new
product development efforts, focus on infectious disease, cardiology,
oncology, drugs of abuse and women's health. Inverness is headquartered in
Waltham, Massachusetts.

This press release may contain forward-looking statements within the
meaning of the federal securities laws. These statements reflect Inverness'
current views with respect to future events and are based on management's
current assumptions and information currently available. Actual results may
differ materially due to numerous factors, including, without limitation,
the demand for Cholestech's products, Inverness' ability to integrate
Cholestech's business with its existing businesses and to recognize the
anticipated benefits of the acquisition, including synergies and accretion,
of the transaction; the risks and uncertainties described in Inverness'
annual report on Form 10-K/A for the period ended December 31, 2006, and
other factors identified from time to time in its periodic filings with the
Securities and Exchange Commission. Inverness undertakes no obligation to
update any forward- looking statements contained herein.

(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...

(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...

(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017 ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...